Short description
TissueGene is a biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders.
Description
TissueGene is a Maryland-based biopharmaceutical company focused on developing regenerative therapies for the treatment of various orthopedic disorders. Founded in 1999, the company’s core technology employs a form of cell therapy to deliver therapeutic proteins directly to localized areas of damaged tissue. The sustained expression of such proteins initiates rapid repair of injured tissue without the need for invasive surgical procedures. TissueGene is currently developing four product candidates, TG-C, TG-B, TG-D, and TG-N for the regeneration of cartilage, bone, disc, and nerve, respectively. The company's lead product candidate, TG-C, has been developed for treating osteoarthritis of the knee and is currently in Phase II trials in the US and in Phase III trials in Korea.
Last funding
Cannot Access
Sign in for full access
Total funding
$$2020202
Sign in for full access
Location
Rockville, Maryland, United States, North America
Founded on
January 1, 1999
Exited on
November 6, 2017
Went public on
November 6, 2017
Stock symbol
950160
Non-profit?
No
Acquired?
No
Employees count
11-50
Revenue range
$56378 - 90123
Sign in for full access